Pharmafile Logo
Pharmafocus logo
Advanced Search

Dermatology

Showing 13 posts of 13 posts found.

Boehringer Ingelheim’s Spevigo gains additional approvals in US and China

March 20, 2024
Medical Communications Boehringer Ingelheim, Dermatology, FDA, Spevigo, psoriasis

Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and Drug Administration (FDA) for the …

News

Sanofi shares phase 2b results for dermatitis treatment

March 12, 2024
Research and Development Dermatology, Sanofi, amlitelimab, atopic dermatitis, clinical trial, dermatitis

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study of amlitelimab for adult patients …

News

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

February 23, 2024
Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …

News

InnoCare shares results from phase 2 trial for atopic dermatitis treatment

December 18, 2023
Research and Development Dermatology, InnoCare, atopic dermatitis, clinical trial

InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met …

News

Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis

November 20, 2023
Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis

Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …

News

FDA accepts Sun Pharma’s NDA for deuruxolitinib

October 6, 2023
Medical Communications Dermatology, FDA, NDA, SUun Pharma, deuruxolitinib

India-based pharma company Sun Pharmaceutical Industries has announced that the US Food and Drug Administration (FDA) has accepted its New …

News

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023
Medical Communications Dermatology, EC, Litfulo, alopecia

Pfizer has announced that the European Commission (EC) has granted marketing authorisation to Litfulo (ritlecitinib) to treat adult and adolescent …

News
money-pills-pharma-file

LEO Pharma to acquire Timber Pharmaceuticals for up to $36m

August 22, 2023
Business Services Dermatology, LEO Pharma, Timber Pharmaceuticals, acquisition

Timber Pharmaceuticals has announced that it has entered a definitive agreement to be acquired by LEO Pharma, with a total …

News
pills-384846_960_720

AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa

July 25, 2023
Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib

AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …

News

Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis

June 28, 2023
Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis

Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …

News

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

May 3, 2023
Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …

News

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

April 27, 2023
Business Services CHMP, Cosentyx, Dermatology, Novartis

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European …

News
Press release

Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis

March 31, 2023
Business Services Almirall, Dermatology, dermatology, lebrikizumab

BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the …

News
Press release

Latest content

Gilead shares phase 3 results from HIV prevention trial

June 21, 2024

Sarepta Therapeutics gains expanded FDA approval for DMD treatment

June 21, 2024

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024

Takeda shares data from phase 3 trial of CIPD treatment

June 20, 2024

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024